Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group

Immune checkpoint inhibition (ICI) triggers immune-related adverse events (irAEs). The relevance of lipase elevation remains unclear. Skin cancer patients with newly detected serum lipase elevation (at least twofold upper normal limit) or newly diagnosed type I diabetes mellitus upon ICI therapy wer...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	European journal of cancer (1990) Ročník 149; s. 1 - 10
Hlavní autoři:	Grimmelmann, Imke, Momma, Michael, Zimmer, Lisa, Hassel, Jessica C., Heinzerling, Lucie, Pföhler, Claudia, Loquai, Carmen, Ruini, Cristel, Utikal, Jochen, Thoms, Kai-Martin, Kähler, Katharina C., Eigentler, Thomas, Herbst, Rudolf A., Meier, Friedegund, Debus, Dirk, Berking, Carola, Kochanek, Corinna, Ugurel, Selma, Gutzmer, Ralf
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Elsevier Ltd 01.05.2021 Elsevier Science Ltd
Témata:	Blood Cancer Colitis Diabetes Diabetes mellitus Diabetes mellitus (insulin dependent) Diabetic ketoacidosis Glucose Immune checkpoint inhibitors Immune-related adverse events Ipilimumab Ketoacidosis Lipase Nivolumab Pancreas Pancreatitis PD-1 inhibitor Pembrolizumab Signs and symptoms Skin cancer Thyroiditis Pembrolizumab Immune-related adverse events Nivolumab Ipilimumab Diabetes mellitus Pancreatitis Immune checkpoint inhibitors PD-1 inhibitor Diabetes Lipase
ISSN:	0959-8049, 1879-0852, 1879-0852
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!